BeOne Medicines revenue and financials

ONC · NASDAQ · USD

$361.51−0.35%−$1.27

Close · October 7, 2026

In the fiscal year ended December 2025, BeOne Medicines reported revenue of $5.34B (+40.23% year over year). Net income was $286.93M, a net margin of 5.4%.

Annual revenue · 2025: $5.34B
  1. $1.07M2016
  2. $238.39M2017
  3. $198.22M2018
  4. $428.21M2019
  5. $308.87M2020
  6. $1.18B2021
  7. $1.42B2022
  8. $2.46B2023
  9. $3.81B2024
  10. $5.34B2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth
+40.23%
2025 vs 2024
Net margin
5.4%
2024: -16.9%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total revenue1,7051,5131,4981,4121,3151,1171,1281,002929752643721
Cost of revenue17516714219716516516117013812511282.7
Gross profit1,5311,3461,3561,2161,151952967831791627531639
Selling, general and administrative593555555529538459505455444427405350
Research and development612541615524525482542496454461484426
Operating income32525018516387.911.1-79.4-120-107-261-381-114
EBIT32525018516387.911.1-79.4-120-107-261-381-114
EBITDA36428921919911842.7-30.4-50.2-83.4-237-359-93.3
Interest expense39.732.932.510.88.07.07.66.14.93.2——
Pre-tax income31225914914799.520.9-85.4-98.3-106-243-320213
Income tax75.531.982.722.35.219.666.523.014.57.714.315.2
Net income23722766.512594.31.3-152-121-120-251-335198
Net income to common shareholders23722766.512594.31.3-152-121-120-251-335198
Basic EPS2.122.050.601.130.870.01-1.43-1.15-1.15-2.41-3.221.88
Diluted EPS2.081.950.521.040.780.01-1.44-1.17-1.17-2.47-3.221.88
Average shares (basic)112111111110108107106106105104104105
Average shares (diluted)116116115115113111106106105104104105